IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer

Gene Therapy

Volumn 4, Issue 10, 1997, Pages 1029-1035

  Traversari, C ^a   Meazza, R ^b,c   Coppolecchia, M ^b   Basso, S ^b   Verrecchia, A ^a   Van der Bruggen, P ^d   Ardizzoni, A ^b   Gaggero, A ^b   Ferrini, S ^b  

^a HSRaffaele   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Antigen presentation; Cytolytic T lymphocytes; Interferon ; Small cell lung cancer; Tumor associated antigens

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MESSENGER RNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA TRANSFECTION; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

EID: 0030862320     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300489     Document Type: Article

References (35)

1. Boon T, Gajewsky TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today 1995; 16: 334-336.
2. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
3. Traversari C et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992; 176: 1453-1457.
4. Weynants P et al. Expression of MAGE genes by non-small-celllung carcinomas. Int J Cancer 1994; 56: 826-829.
5. Boel P et al. BAGE a new gene encoding for an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167-175.
6. Van den Eynde B et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 1892: 689-698.
7. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy, where are we now? Immunol Today, 1994; 15: 48-51.
8. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995; 13: 3399-3415.
9. Gansbacher B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
10. Fearon ER et al. Interleukin-2 production bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
11. - T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149: 3627-3635.
12. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis-α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
13. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25: 1137-1140.
14. Ihde DC. Current perspectives in the treatment of small cell lung cancer: educational symposium of the VII World Congress on Lung Cancer. Lung Cancer 1995; 12 (Suppl. 3): 1-3.
15. Dalmau J et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer: a quantitative and Western blot analysis. Ann Neurol 1991; 27: 544-552.
16. Darnell RB, Deangelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341: 21-22.
17. Clamon G et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of cancer and leukemia group B. J Natl Cancer Inst 1993, 85: 316-320.
18. Cassileth PA. Phase I study of transfected cancer cells expressing the IL-2 gene product in limited stage SCLC. Hum Gene Ther 1995; 6: 369-383.
19. Meazza R et al. Analysis of IL-2 receptor expression and of the biological effect of transfection in small-cell lung cancer. Br J Cancer 1996; 74: 788-795.
20. Doyle A et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985; 161: 1135-1151.
21. Van der Bruggen P et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolyric T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 3038-3043.
22. Nijman HW et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 1215-1219.
23. Marchand M et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 883-885.
24. Gaugler B et al. Human MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179: 921-930.
25. Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
26. Garrido F et al. Natural history of HLA expression during tumor development. Immunol Today 1993; 14: 491-499.
27. Lehman F et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340-347.
28. Powis SH et al. Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex. Proc Natl Acad Sci USA 1992; 89: 1463-1467.
29. Benham A, Tulp A, Neefjes J. Synthesis and assembly of MHC-peptide complexes. Immunol Today 1995; 16: 359-362.
30. Ogasawara M, Rosenberg SA. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Cancer Res 1993; 53: 3561-3568.
31. Rorenthal FM et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferons-γ cDNAs. Blood 1994; 83: 1289-1298.
32. De Leij L et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985; 45: 6024-6033.
33. Meazza R et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 1996; 12: 2187-2192.
34. Long EO et al. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum Immunol 1991; 31: 229-235
35. Espevik T, Nissen-Mejer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Meth 1986; 95: 99-105.